KAKailash

Kailash

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kailash has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Results of treatment of patients with posterior mediastinal neuroblastoma in the observation group

    by T. V. Shamanskaya, D. D. Kisurina, O. I. Bydanov, I. G. Khamin, D. M. Konovalov, V. Yu. Roshchin, N. A. Andreeva, G. V. Tereshchenko, A. P. Shcherbakov, Yu. N. Likar, et al.

    Background . Neuroblastoma (NB) with primary tumor located in the posterior mediastinum is a unique subgroup characterized by a higher incidence of life-threatening complications, such as epidural compression (EC) and respiratory failure, yet it is associated with favorable long-term outcomes. Materials and methods . The study included patients with low-risk posterior mediastinal NB treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between January 2012 and September 2024 (152 months). Patients were stratified into risk groups and managed according to the GPOH-NB2004 protocol. We evaluated relapse/progression detection methods, disease characteristics, treatment approaches, and long-term outcomes. Results . The study included 146 patients with NB with primary tumor located in the posterior mediastinum, which is 21.6 % of all patients in the observation (low-risk) group registered in the research database of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The median age at diagnosis was 19.6 months (range 0.5–132.5 months) with a female predominance (male-to-female ratio 1:1.2). Most patients (85/146; 58.2 %) presented with stage 2 disease. 38/146 (26.0 %) patients received chemotherapy due to life threatening symptoms, primarily EC, while 87/146 (59.6 %) patients underwent best surgery in the volume of a macroscopic residual tumor. Relapse/progression occurred in 16.4 % (24/146), predominantly detected during routine follow-up imaging (18/24; 75,0 %), with a median time to relapse of 7.8 months (range 3.0–25.3 months). The majority of relapses/progressions were local (18/24; 75.0 %). In 93 % (14/15) of relapsed/progressed cases analyzed retrospectively, MLPA revealed segmental chromosomal aberrations (median 3 aberrations/ patient; range 0–6). The most frequent alterations included 17q gain (n = 11), 2p gain (n = 8), and deletions in 3p (n = 6), 11q (n = 5), and 4q (n = 4). The 5-year event-free survival in patients with mediastinal NB was 79,1 ± 4,0 %, patients with stage 1 showing the highest survival rates (90 ± 6 %) (p = 0.1932). The 5-year overall survival was 95,0 ± 2,1 %. The cumulative incidence of relapse/progression was 18.7 ± 3.5 %, while treatment-related mortality was 2.8 ± 1.4 % (one death from disease progression; five from therapy toxicity). Conclusions. Mediastinal NB is a prognostically favorable group, with excellent survival rates independent of age or stage. Most patients in the low-risk group achieved favorable outcomes, even after relapse/progression. For the majority of patients in the low-risk group, surgery only is sufficient, and this strategy allows to reduce the risk of mortality from the toxicity of therapy without reducing overall survival. However, chemotherapy remains critical for patients with life-threatening complications, such as EC and respiratory failure, which once again highlighting the challenges in managing this subgroup. Strict adherence to the entire follow-up plan during the period of catamnesis is essential for early relapse detection. The molecular profile of the tumor may predict relapses and treatment response, which underscores the need to integrate molecular diagnostic methods (MLPA) to all patients with NB in the low-risk group into routine diagnostics.

  • Open Access

    Radiation therapy to metastatic sites among patients with high-risk neuroblastoma in first-line therapy

    by T. V. Shamanskaya, Yu. M. Voevodina, A. Yu. Usychkina, Yu. N. Likar, Ch. Kailash, M. M. Dunaykin, D. Yu. Kachanov, A. V. Nechesnyuk

    Relevance. Radiation therapy (RT) is one of the components of multimodal treatment among patients with high-risk neuroblastoma (NB), and in combination with surgical treatment is a mandatory element of local control of the primary tumor. At the same time, RT for metastatic sites persisting after completion of induction therapy is not a standard protocol treatment in primary patients with high-risk NB. The effect of RT on metastatic sites on improving long-term survival and reducing recurrence rates continues to be studied.Aim to the study – to investigate approaches to RT for single metastatic foci persisting after induction therapy among patients with NB highrisk group as part of the consolidation phase of first-line therapy.Materials and methods. The retrospective analysis included 11 patients with high-risk NB who underwent RT for metastatic foci as part of first-line therapy at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia from 01.2012 to 12.2023. Patients received therapy according to the modified protocol GPON-NB2004. The indication for RT was the persistence of a single metastatic site detected by 123I-metaiodobenzylguanidine scintigraphy or computed tomography/magnetic resonance imaging after completion of induction chemotherapy.Results. The median age was 31.9 months (range 9.4–128.6 months). All patients were initially with stage 4 disease (one patient had metastatic focus in the orbit without detection of the primary tumor). MYCN gene amplification was detected in 4/11 (36 %) cases. 10/11 (91 %) patients achieved а partial response after induction therapy. In all cases, only one metastatic focus was irradiated. 2/11 patients received radiation to both the primary tumor and metastatic focus.10/11 patients received RT to metastatic sites localized in skeletal bones, 1/11 – to a distant lymph node. Seven of 11 sites received 21 Gy in 14 fractions. The median follow-up was 40 months (range 13–97 months). Only 1 of 11 patients receiving metastatic site irradiation experienced relapse in an irradiated distant site 24 months later. The 3-year relapse-free survival and overall survival were 54 % and 80 % respectively.Conclusions. RT may be an effective method of local control in oligometastatic disease and in case of persisted single metastatic foci after induction chemotherapy in the treatment of high-risk NB. Additional large studies are needed to confirm the role of RT in improving survival with irradiation of metastatic sites.

  • Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin’s lymphoma

    by Mikhail Ya. Yadgarov, M. M. Dunaykin, G. I. Shestopalov, C. Kailash, E. D. Kireeva, N. V. Myakova, Yu. N. Likar

    Hodgkin lymphoma (HL) in pediatric populations has a high survival rate but poses risks for long-term morbidities. Although [18F]fluoro‑2‑deoxy‑2‑d‑glucose positron emission tomography ([18F]FDG PET) scans offer potential for improved risk stratification, the definitive prognostic value of quantitative [18F]FDG PET parameters remains unclear for pediatric HL. A single-center, retrospective study included pediatric patients diagnosed with HL between 2016 and 2023 treated according to EuroNet-PHL-C1 and DAL/GPOH-HD protocols. Patients underwent baseline and interim PET/CT scans after two chemotherapy cycles. Event-free survival (EFS) was the primary endpoint, Deauville score was the secondary endpoint. Quantitative [18F]FDG PET parameters included SUVmax, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) that were evaluated using two segmentation methods (SUV 2.5, 41% SUVmax). Survival outcomes were assessed using Cox regression analysis. A total of 115 patients (50 males, median age 14.2 years) were studied, with a median follow-up period of 35 months. During this period, 16 cases (13.9%) of relapse or progression were noted. Baseline and interim MTV 2.5, MTV 41%, TLG 2.5, and TLG 41%, along with interim SUVmax, were significantly associated with worse EFS and correlated with post-treatment Deauville scores. In multivariable analysis, interim MTV 2.5 > 0 ml (adj. hazard ratio, HR: 3.89, p = 0.009) and interim TLG 41% ≥ 30 g (adj. HR: 7.98, p = 0.006) were independent risk factors for EFS. Baseline and interim [18F]FDG PET parameters can serve as significant prognostic indicators for EFS and treatment response in pediatric HL. These quantitative measures could enhance individualized, risk-adapted treatment strategies for children and adolescents with HL.


  • Open Access

    The diagnostic roles of fused 18F-fluorodeoxyglucose positron emission tomography/computed tomography and bone scintigraphy in children and young adults with bone sarcomas: a systematic review and meta-analysis

    by M. Ya. Yadgarov, E. D. Kireeva, Kailash, M. M. Dunaikin, Yu. N. Likar, Кайлаш

    Osteosarcoma and Ewing sarcoma are the most common primary malignant bone diseases in children. An accurate diagnosis and staging of these tumors play a pivotal role in choosing the optimal treatment and predicting outcomes. In recent years, fused 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) has been increasingly used in the diagnosis of bone sarcomas. It is frequently applied in conjunction with, or as a replacement for bone scintigraphy (BS), in order to determine the extent of the disease. However, the questions on the diagnostic significance of these methods and the choice of the most effective approach to the management of children with bone sarcomas still remain unanswered. We conducted a systematic review and meta-analysis to compare the diagnostic roles of 18F-FDG PET/CT and BS in staging and restaging of bone sarcomas in children and young adults. The study was carried out in accordance with the Cochrane PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Two independent researchers looked for prospective and retrospective studies evaluating the sensitivity and specificity of 18F-FDG PET/CT and BS in staging and restaging of bone sarcomas in children and young adults, published over the last 15 years. The quality of the included studies was assessed using the QUADAS-2 tool. Summary Receiver Operating Characteristic curves were calculated using STATA 17 software packages and the RevMan 5.3 tool to evaluate the overall diagnostic value of PET/CT and BS. The certainty of evidence was evaluated using the GRADE system. This systematic review and meta-analysis included 8 studies (530 patients with bone sarcomas). These studies used 11 patient cohorts (osteosarcoma: 5 cohorts, 305 patients; Ewing sarcoma: 6 cohorts, 225 patients). We discovered that 18F-FDG PET/CT had high sensitivity in staging and restaging of bone sarcomas (94% (95% confidence interval (CI) 89–97)). On the other hand, BS demonstrated lower sensitivity (69% (95% CI 58–79), the mean difference being 25% (95% CI 18.89–31.00), p 0.001). At the same time, the specificity of 18F-FDG PET/CT and the specificity of BS were found to be comparable (96% (95% CI 83–99) and 92% (95% CI 82–97) respectively, p = 0.15). All the results were confirmed in a subgroup analysis of patients with osteosarcoma and Ewing sarcoma. The results of our systematic review and meta-analysis lead us to conclude that 18F-FDG PET/CT is a more sensitive method for staging and restaging of bone sarcomas in children and young adults, compared to BS. However, both methods have high specificity. Considering our findings, future clinical research in children with bone sarcomas should be aimed at further data collection to clarify the diagnostic roles of 18F-FDG PET/CT and BS both in children with osteosarcoma and in children with Ewing sarcoma, in order to identify clear indications and choose the best imaging method for detecting metastatic bone lesions, with the aim of developing an optimal diagnostic strategy.


  • Open Access

    Visual and quantitative assessment of interim 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in children with Hodgkin lymphoma

    by M. M. Dunaikin, G. I. Shestopalov, M. Ya. Yadgarov, Ch. Kailash, E. D. Kireeva, N. V. Myakova, Yu. N. Likar

    The use of risk-adaptive therapy in patients with Hodgkin lymphoma (HL) makes it possible to de-escalate treatment protocols, thereby decreasing the incidence of long-term adverse effects. Metabolic remission as detected by interim positron emission tomography/computed tomography (PET/CT) performed after 2 cycles of chemotherapy is a prognostic factor that could guide further treatment. The generally accepted Deauville 5-point scale (DS) used for the visual assessment of interim PET/CT scans may be prone to inaccuracies. One of the suggested ways to address this problem is to use a quantitative evaluation method (qPET).   The aim of our study was to determine the level of discrepancy between DS assigned after visual (vDS) and quantitative (qDS) assessment of detected lesions on interim PET/CT images in children with HL. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Interim PET/CT scans of 115 patients with HL (the median age was 14 years) were retrospectively analyzed using the quantitative (qPET) method to determine qDS. Baseline PET/CT scan findings and medical history data were available for all patients. All imaging studies were performed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between June 2016 and March 2023. Our results showed that with the above approach (availability of initial PET/CT scans and access to the patient’s medical history), discordance between vDS and qDS was about 30%. There was no difference in the patients with a DS of 4 and 5. In other cases, in 31 (27%) patients, vDS and qDS differed by one score: 25 patients with a qDS of 2 had a vDS of 3; 6 patients with a qDS of 3 had a vDS of 4. Factors independently associated with event-free survival were vDS (hazard ratio (HR) 2.49 (1.26–4.93), p = 0.009) and the presence of a bulky tumor (HR 3.12 (1.10–9.64), p = 0.048). Our comparative analysis revealed a discrepancy between the findings obtained by the visual and quantitative assessment methods. In our study, there were no cases of vDS underestimation and, as a consequence, no patients underwent treatment de-escalation. In HL patients with good tumor volume reduction on CT but ambiguous results of interim PET/CT evaluation performed using the vDS (especially in case of DS4 or DS3), quantification software should be used.

  • Open Access

    Atypical Uptake of 18FDG in White Adipose Tissue During PET/CT in Children

    by M. M. Dunaikin, Ch. Kailash, E. D. Kireeva, N. L. Komarova, Yu. N. Likar

    Positron emission tomography combined with computed tomography (PET/CT) with 18F-fluoro-deoxyglucose (18F-FDG) plays an important role in the management of cancer patients and is mainly used for primary staging, evaluation of treatment response and detection of disease recurrence. Due to non-specific nature of 18F-FDG uptake, a radiologist must be familiar with both physiological and atypical distribution of radiopharmaceuticals. Inappropriate patient preparation for the study and/or taking certain drugs can lead to abnormal 18F-FDG distribution. Our clinical case demonstrates an atypical uptake of 18F-FDG in white adipose tissue in a child treated with glucocorticoids for a long time.

  • Open Access

    Accumulation of 123I-mIBG in the Gallbladder in a Child with Ganglioneuroblastoma

    by N. L. Komarova, Е. Д. Киреева, . . Kailash, M. M. Dunaikin, Yury Likar

    A 6-year-old boy with ganglioneuroblastoma, received 4 courses of chemotherapy and underwent partial resection of the tumor. The control scintigraphy with 123I-metaiodobenzylguanidine (123I-mIBG) was performed, including the single photon emission computed tomography protocol combined with computed tomography (SPECT/CT), revealing the residual tumor with pathological uptake of 123I-MIBG. In addition to this, there was a focal uptake of 123I-mIBG in the gallbladder. In this clinical case we have demonstrated an atypical uptake of 123I-mIBG in the gallbladder.

  • Open Access

    The value of single-photon emission computed tomography combined with computed tomography imaging in ¹²³I-Metaiodobenzylguanidine scintigraphy in children with neuroblastoma

    by E. D. Kireeva, Kailash, T. V. Shamanskaya, M. Ya. Yadgarov, D. Yu. Kachanov, Yu. N. Likar, Кайлаш, М. Я. Ядгаров

    The value of single-photon emission computed tomography combined with computed tomography imaging in ¹²³I-Metaiodobenzylguanidine scintigraphy in children with neuroblastomaWhole body scintigraphy with ¹²³I-Metaiodobenzylguanidine (¹²³I-MIBG) is an important imaging modality for evaluation of patients with neuroblastoma (NB). As the intrinsic nuclear scintigraphic characteristics, the assessment of conventional planar ¹²³I-MIBG images presents some difficulties. The limited resolution of planar images can induce false-negative results for small lesions, whereas the presence of physiologic MIBG uptake is not always easily differentiable from pathologic uptake and can induce false-positive results. Single-photon emission computed tomography combined with computed tomography (SPECT/ CT) hybrid imaging technique, allowing the direct fusion of morphologic and functional information, has been suggested to be more accurate. However, SPECT/CT imaging renders slightly more radiation to patients from CT portion of the study and is time consuming. The aim of our study was to investigate how much SPECT/CT can have additional diagnostic value over planar imaging in NB patients at initial staging. The study was approved by the Independent Ethics Committee and the Scientific Council of the D. Rogachev NMRCPHOI. A total of 251 SPECT/CT scans following by planar ¹²³I-MIBG imaging scans performed in 251 patients with NB were retrospectively analyzed. In 72.1% of the studies, the whole-body planar images and SPECT/CT images showed the same result. In 27.9% of studies, however, SPECT/CT images provided additional very important information. In our study, the diagnosis reached by planar imaging was revised or specified by SPECT/CT in 70 of the 251 patients and was clinically significant.


  • Open Access

    Indication of 99mTc-MDP bone scan after 123I-MIBG scintigraphy in patients with neuroblastoma

    by Kailash, E. D. Kireeva, I. S. Vdovina, T. V. Shamanskaya, D. Y. Kachanov, S. R. Varfolomeeva, Y. N. Likar

    123I-MIBG (metaiodobenzylguanidine) scintigraphy and 99mTc-MDP bone scintigraphy (bone scan) are widely used in diagnosis and staging of NB. Consecutively using both methods lead to overall radiation exposure. As most of the patients need additional anesthesia to perform these diagnostic procedures, which accordingly increase the side effect, workload and expenditure. To minimize the exposure, side effect, workload and expenditure, we set the tasks to optimize the diagnostic algorithm. Determine the indications of bone scan after 123I-MIBG scintigraphy. Materials and Methods: 129 patients with NB were included in retrospective study who underwent both diagnostic procedures at interval of less than 30 days at the stage of initial diagnostic procedure using standard protocols. Out of 83 MIBG positive patients bone scan was able to detect metastatic lesions only in 48 patients. However, bone scan had revealed metastatic lesions in 3 out of 14 MIBG-negative patients. Bone scan is indicated only in MIBG-negative neuroblastoma patients; and in cases where the MIBG uptake cannot be determined for example after operative treatment or after starting of chemotherapy.